Patents Examined by Keith D. MacMillan
-
Patent number: 6143305Abstract: Endogenous and exogenous proteins, and fragments thereof, are chemically modified outside the body of an animal so that when injected into the animal they produce more antibodies against the unmodified protein than would injection of the unmodified protein or fragment alone. The chemical modification may be accomplished by attaching the proteins or fragments to carriers such as, for example, bacterial toxoids. The chemical modification can also be accomplished by polymerization of protein fragments. Proteins which can be modified include Follicle Stimulating Hormone and Human Chorionic Gonadotropin. The modified polypeptide may be administered to animals for the purpose of contraception, abortion or treatment of hormone-related disease states and disease disorders, treatment of hormone-associated carcinomas, and to boost the animals' resistance to exogenous proteins, for example viral proteins.Type: GrantFiled: June 6, 1995Date of Patent: November 7, 2000Assignee: The Ohio State UniversityInventor: Vernon C. Stevens
-
Patent number: 6140099Abstract: The invention relates to compositions and methods for delaying the onset of fetal membrane rupture in a human. The method comprises administering to the human a metalloproteinase-9 inhibitor in an amount effective to delay the onset of fetal membrane rupture in the human.Type: GrantFiled: December 18, 1997Date of Patent: October 31, 2000Assignee: The Trustees of the University of PennsylvaniaInventor: Jerome Strauss, III
-
Patent number: 6140359Abstract: A pharmaceutical formulation of paclitaxel (also known as taxol) and polyethoxylated castor oil is disclosed to be relatively acidified to a pH of less than 8.1 and preferably within a pH range of 5 to 7, inclusively. Ethanol is optionally included in the formulation which is adapted for use in a body for the treatment of cancer. A formulation method is disclosed and includes the step of mixing an acid with a carrier material, such as polyethoxylated castor oil, to form a carrier solution after which taxol is added in an amount such that the resulting pH is less than 8.1 and preferably in a pH range of 5 to 7. Ethanol may optionally be slurried with the paclitaxel before mixing with the carrier solution. A variety of acidifying agents, a preferred one being anhydrous citric acid, are described.Type: GrantFiled: July 19, 1999Date of Patent: October 31, 2000Assignee: NaPro Biotherapeutics, Inc.Inventors: David Carver, Timothy Prout, Hernita Ewald, Robyn Elliott, Paul Handreck
-
Patent number: 6140371Abstract: A number of new therapeutic uses have been found for compounds such as known local anesthetics which are quite different from the present therapeutic uses of these drugs. The uses include, for example; modulating lymphocytes, macrophages and other immune cell functions, or PMN functions; inhibiting the cytotoxic effect of polymorphonuclear neutrophils leucocytes; providing a protective effect on plasma cell membranes; and providing an antidote against intoxication by an intoxicants.Type: GrantFiled: February 19, 1998Date of Patent: October 31, 2000Assignee: Medipharma S.A.Inventors: Juan Carlos Mahiques, Ricardo Luis Elicabe, Raul Isidoro Koler, Ruben Martin Laguens, Enrique Leo Portiansky
-
Patent number: 6140373Abstract: The present invention is directed to a sterile pharmaceutical composition comprising a propofol containing oil-in-water emulsion formulation having as an antimicrobial agent, a member selected from the group consisting of benzyl alcohol and ethylene diamine tetra acetic acid; benzethonium chloride; and benzyl alcohol and sodium benzoate.Type: GrantFiled: October 23, 1998Date of Patent: October 31, 2000Assignee: Abbott LaboratoriesInventors: Thomas May, John Hofstetter, Kathleen L. Olson, Sukumaran K. Menon, Bernard A. Mikrut, Clayton S. Ovenshire, Lawrence John Rhodes, Earl R. Speicher, James R. Waterson
-
Patent number: 6137004Abstract: Described are preferred processes for recovering citric acid from a medium in which it is contained. The citric acid is recovered both effectively and in a form which is readily purifiable. In one preferred process, the citric acid-containing medium is contacted with a solid-phase free base resin having tertiary amine groups to adsorb the citric acid. The citric acid is then desorbed by displacement with a stronger acid, and a citric acid-containing fraction is collected substantially free from contamination by the stronger acid. In another preferred process, a citric acid-containing medium is contacted with a solid-phase divinylbenzene-crosslinked polymer having pyridine or aliphatic tertiary amine functions to adsorb citric acid, the contacting being at a temperature below about 40.degree. C. Adsorbed citric acid is then desorbed with hot H.sub.2 O at a temperature of at least about 75.degree. C.Type: GrantFiled: June 7, 1995Date of Patent: October 24, 2000Assignee: Reilly Industries, Inc.Inventors: Donald W. McQuigg, Charles Marston, Gina Fitzpatrick, Ernest Crowe, Susan Vorhies
-
Patent number: 6136862Abstract: A cerebral function improving agent containing as the active ingredient a compound represented by the following formula: ##STR1## wherein R.sub.2 represents a hydrogen atom when R.sub.1 is a hydroxyl group;or R.sub.1 or R.sub.1 are combined together to form an oxo group;R.sub.3 represents a hydrogen atom, an alkali metal, or a monohydric, dihydric or trihydric alcohol residue,which may be an oligomer composed of 2-10 molecules when R.sub.1 represents a hydroxyl group and R.sub.2 and R.sub.3 represent hydrogen atoms.The agent suppresses cerebral edema, protects cerebral function, impaired cerebral energy metabolism, and reduces the extent of cerebral infarction.Type: GrantFiled: November 26, 1996Date of Patent: October 24, 2000Assignee: Shimizu Pharmaceutical Co., Ltd.Inventors: Atsushi Hiraide, Sekiko Dohi, Motohisa Suzuki, Yoshihiro Shiba
-
Patent number: 6126916Abstract: Novel metal binding ligands are disclosed that may be coupled to peptides for use in methods of diagnosis and therapy. Peptides containing the ligands are produced using a method wherein ligand introduction or cyclization can be conducted at any point during the synthesis of the peptide. Such peptide derivatives are readily labeled with radiometals, such as isotopes of rhenium or technetium, while retaining their ability to tightly bind specific peptide receptors.Type: GrantFiled: July 11, 1997Date of Patent: October 3, 2000Assignee: Immunomedics, Inc.Inventors: William J. McBride, Gary L. Griffiths
-
Automated analysis equipment and assay method for detecting cell surface protein function using same
Patent number: 6127133Abstract: Automated drug screening method and a method of studying receptor and ion-channel activity are provided.Type: GrantFiled: April 18, 1994Date of Patent: October 3, 2000Assignee: Sibia Neurosciences, Inc.Inventors: Michael Anthony Akong, Michael Miller Harpold, Gonul Velicelebi, Paul Brust -
Patent number: 6127519Abstract: Peptides useful in the regulation of calcium metabolism are disclosed. Also disclosed are pharmaceutical compositions of matter containing such peptides as well as a method for the regulation of calcium metabolism in a patient in need of such treatment. The peptides contain modified or unmodified portions of an amino acid sequence at the 8- to 32-positions of native calcination.Type: GrantFiled: December 21, 1990Date of Patent: October 3, 2000Assignee: Tsumura & Co.Inventors: Ronald C. Orlowski, Satoshi Hanamura, Masahiko Marumoto, Kenji Sakamoto, Yoshihiro Waki
-
Patent number: 6124101Abstract: The DNA encoding the cell surface receptor for thrombin has been cloned and sequenced. The availability of this DNA permits the recombinant production of thrombin receptor which can be produced at cell surfaces and is useful in assay systems both for the detection of thrombin and for the evaluation of candidate thrombin agonists and antagonists. Further, the elucidation of the structure of the thrombin receptor permits the design of agonist and antagonist compounds which are useful diagnostically and therapeutically. The availability of the thrombin receptor also permits production of antibodies specifically immunoreactive with the receptor per se or with specific regions thereof which are also useful diagnostically or therapeutically.Type: GrantFiled: June 7, 1995Date of Patent: September 26, 2000Assignees: The Regent of the University of California, COR Therapeutics, Inc.Inventor: Shaun R. Coughlin
-
Patent number: 6120777Abstract: The present invention relates to a malondialdehyde-acetaldehyde adduct which acts as a specific immune-enhancing factor. In addition to its highly specific and immunogenic properties, the factor is highly fluorescent. It has an excitation frequency of about 398 nanometers and an absorbance of about 460 nanometers. The factor is also highly reactive and is also adducted to antigens including complex proteins, lipids, carbohydrates or DNA.Type: GrantFiled: May 27, 1997Date of Patent: September 19, 2000Assignee: The Board of Regents of the University of NebraskaInventors: Geoffrey M. Thiele, Thomas L. McDonald, Dean J. Tuma, Lynell W. Klassen, Michael F. Sorrell
-
Patent number: 6117982Abstract: Several forms of immunoregulatory substances are derived from monoclonal antibodies (MAbs) that are specific for a T cell surface antigen, such as CD3, TCR, CD4, or CD8 on T cells. The substances include: a mixture of F(ab').sub.2 fragments (or other divalent binding molecules which lack Fc) which each bind noncompetitively to different monovalent antigenic epitopes on the same antigen; a conjugate including a polymer molecule, such as dextran, ficoll, or agarose, that is coupled with the binding molecules, e.g., Fv, Fab, or F(ab').sub.2, which bind to monovalent antigenic epitopes on the same antigen on T cells; a conjugate including a liposome or microbead that is coupled with the same binding molecules specific for a T cell surface antigen.Type: GrantFiled: April 8, 1993Date of Patent: September 12, 2000Assignee: Tanox, Inc.Inventor: Tse Wen Chang
-
Patent number: 6113887Abstract: There is disclosed a toothpaste composition containing: (1) a water-soluble bactericide selected from the group consisting of pyridinium compounds, quaternary ammonium compounds and biguanide compounds in an amount of 0.001% to 5.0% by weight, based on the total weight of the composition; (2) a cationically-modified hydroxyethylcellulose having an average molecular weight of 1,000,000 or higher in the hydroxyethylcellulose portion thereof and having a cationization degree of 0.05 to 0.5 mol/glucose in an amount of 0.5% to 5.0% by weight, based on the total weight of the composition; (3) a surfactant selected from the group consisting of polyoxyethylene polyoxypropylene block copolymers and alkylolamide compounds in an amount of 0.5% to 13% by weight, based on the total weight of the composition; and (4) a polishing agent of the non-silica type in an amount of 5% to 50% by weight, based on the total weight of the composition.Type: GrantFiled: December 21, 1993Date of Patent: September 5, 2000Assignee: Sunstar Kabushiki KaishaInventors: Shigeki Mori, Takako Nakajima
-
Patent number: 6114508Abstract: The ethyl ester of derivatives of benzoyl ecgonine are provided having a linking group at the para position of the benzoyl group. The derivatives are used to bond to immunogenic polypeptides for production of antisera and monoclonal antibodies. The antisera and antibodies find use in assays, for treatment of cocaine overdose and detoxification.Type: GrantFiled: August 25, 1998Date of Patent: September 5, 2000Assignee: DrugAbuse Sciences, Inc.Inventors: Jean-Michel Scherrmann, Philippe Pouletty, Herve Galons
-
Patent number: 6114303Abstract: Low doses of stroma-free diaspirin cross-linked hemoglobin are administered to patients undergoing hemodialysis, to achieve hemostabilization and avoid hypotensive episodes in susceptible patients. Hemoglobin therapy when implemented prophylactically in hemodialysis also partially obviates the need for further interventions to control circulatory system instability.Type: GrantFiled: May 3, 1999Date of Patent: September 5, 2000Assignee: Baxter International, Inc.Inventors: John Blue, Jan W. Garber, Janet C. Gonder, Gary R. Marchand, Robert J. Przybelski, Kathleen N. Stern
-
Patent number: 6110477Abstract: A stable composition is provided to treat and/or prevent photo-aged skin and related skin disorders such as sunburn, wrinkles, poor skin tone and skin discoloration by topically applying to the skin the treatment composition containing an effective amount of a compound such as ascorbic acid, derivatives of ascorbic acid and/or extracts containing ascorbic acid, in a pharmaceutically acceptable vehicle containing a substantially anhydrous base having no water added. The anhydrous base stabilizes the compound, so that the compound remains effective for an effective period of time, even in the presence of exposure to water. Preferably, the anhydrous base is a single phase carrier, as opposed to a two phase carrier emulsion.Type: GrantFiled: October 30, 1998Date of Patent: August 29, 2000Assignee: Topix Pharmaceuticals Inc.Inventors: Steven Hernandez, Burt Shaffer
-
Patent number: 6107275Abstract: The present invention relates to cyclic peptide analogs containing a pseudo-bond, useful as platelet aggregation inhibitors. An example of a compound of this invention includes Cyclo[Ala.PSI.[CH.sub.2 NH]-Arg-Gly-Asp-.delta.-Glu](NHBn).cndot.CF.sub.3 CO.sub.2 H. These compounds inhibit the binding of fibrinogen to the platelet GPIIb-IIIa integrin receptor which inhibits platelet aggregation and therefore these compounds act as potent antithrombotics.Type: GrantFiled: April 9, 1997Date of Patent: August 22, 2000Assignee: Merrell Pharmaceuticals Inc.Inventors: Scott L. Harbeson, Alan J. Bitonti
-
Patent number: 6105591Abstract: A method is disclosed for cleaning a black powder firearm with a patch saturated with an aqueous emulsion. The aqueous emulsion includes a detergent, a lower alcohol and an essential oil. The saturated patch is loaded into a charged firearm with a projectile, and the firearm is then discharged.Type: GrantFiled: June 4, 1996Date of Patent: August 22, 2000Inventors: Thomas John DeCare, Leslie Allen Phelps, Leslie Harold Volles
-
Patent number: 6106835Abstract: Several forms of immunoregulatory substances are derived from monoclonal antibodies (MAbs) that are specific for a T or B cell surface antigen, such as CD3, TCR, CD4, or CD8 on T cells or membrane-bound immunoglobulins on B cells. The substances include: a mixture of F(ab').sub.2 fragments (or other divalent binding molecules which lack Fc) which each bind noncompetitively to different monovalent antigenic epitopes on the same antigen; the F(ab').sub.2 fragment (or other divalent binding molecules which lack Fc) of a bispecific antibody which has each of its binding sites derived from one of the two MAbs that bind noncompetitively to monovalent antigenic epitopes on the same antigen; a conjugate including a polymeric backbone, such as polyethylene glycol ("PEG"), cellulose, dextran, agarose, or an amino acid copolymer or a liposome, that is coupled with the binding molecules, e.g., Fv, Fab, or F(ab').sub.2, which bind noncompetitively to monovalent antigenic epitopes on the same antigen.Type: GrantFiled: January 28, 1993Date of Patent: August 22, 2000Assignee: Tanox, Inc.Inventor: Tse Wen Chang